Alpa Laboratories profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Returns
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
8.4%8.4%12.1%11.7%9.9%
6.5%6.5%9.6%9.6%7.8%
0.7%0.7%1.5%4.2%4.6%
−4.7%2.0%3.2%7.6%8.8%
Margins
−1.0%3.1%4.2%7.5%8.2%
1.1%1.1%2.3%5.7%6.7%
—20.4%−97.0%−0.5%—
5.3%15.8%22.8%19.0%17.2%
4.0%14.2%17.3%15.4%13.7%
——17.3%—13.7%
5.7%5.7%−3.8%−2.5%−6.5%
Additional
25.9%10.1%24.0%18.9%20.8%
8.4%8.4%12.1%11.7%9.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALPA₹52.62

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹111 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity9.8611.7112.068.398.39
Return on Assets7.839.589.636.466.46
Return on Capital Employed4.554.231.540.660.66
Return on Invested Capital8.817.573.182.03-4.67
Margins
EBITDA Margin8.177.454.233.11-0.99
Operating Margin6.745.662.271.131.13
Incremental Operating Margin—-0.49-96.9720.36—
Pretax Margin17.2419.0222.8215.785.34
Net Income Margin13.6715.4317.3414.193.96
Net Income to Common Margin13.67—17.34——
FCF Margin-6.46-2.52-3.845.675.67
Additional
Effective Tax Rate20.7518.8824.0110.1125.92
Sustainable Growth Rate9.8611.7112.068.398.39
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.